Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes AI

The Future of Longevity: AI and Nanorobots to Radically Extend Life

by Team Lumida
June 25, 2024
in AI, Health and Longevity
Reading Time: 3 mins read
A A
0
person holding black and white microscope

Photo by Jaron Nix on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

  1. AI-driven drug discovery could drastically cut down clinical trial times.
  2. Medical nanorobots may revolutionize immune systems by the 2030s.
  3. By 2040s, mind-backup systems might allow near-immortality.

What Happened?

Futurist Ray Kurzweil claims that AI will revolutionize drug discovery and medical interventions by the end of the 2020s. He believes biological simulators will soon generate crucial safety and efficacy data in hours, not years.

This shift could lead to faster drug approvals and save countless lives. Kurzweil also predicts that medical nanorobots will emerge in the 2030s, vastly enhancing our immune systems and treating metabolic diseases. By 2040s, he envisions mind-backup systems that could essentially render death obsolete.

Why It Matters?

These advancements could disrupt traditional medical models and extend human lifespans dramatically. Faster drug approvals would mean quicker access to lifesaving treatments. Medical nanorobots could address diseases that our natural immune systems can’t, such as cancer and neurodegenerative disorders.

The potential to back up our minds might lead to radical life extension, fundamentally changing the concept of mortality. Investors should note the profound implications for the healthcare and biotech sectors, which could experience exponential growth.

What’s Next?

Expect increased investment in AI-driven pharmaceutical research and biotech firms focused on nanotechnology. Regulatory landscapes will evolve to accommodate simulated trials, despite potential bureaucratic resistance. By the mid-2040s, mind-backup technologies will likely face ethical and security challenges, but Kurzweil is optimistic about overcoming these hurdles.

As these technologies become mainstream, they will likely follow the trajectory of the cell phone—starting expensive and exclusive, but eventually becoming widely accessible.

Source: Fortune Well
Tags: AI-driven drug discoverymedical nanorobotsmind-backup systemsRay Kurzweil
Previous Post

Bitcoin Crashes to $62K: What’s Behind the $150M Liquidation?

Next Post

TikTok Ban Could Dent Oracle’s Earnings: What Investors Need to Know

Recommended For You

China Kills Meta’s $2.5B Manus Deal — And Sends a Warning to Every Chinese AI Founder

by Team Lumida
19 minutes ago
China’s Manufacturing Powerhouse Faces Domestic Struggles: What It Means for Global Investors

China banned Meta's acquisition of AI agent startup Manus on national security grounds, giving both companies weeks to fully unwind the deal and restore all transferred data and...

Read more

OpenAI Missed Its User and Revenue Targets — and Its CFO Is Worried About Paying for $600B in Data Center Commitments

by Team Lumida
20 minutes ago
OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

OpenAI failed to hit its internal goal of 1 billion weekly ChatGPT users and missed annual revenue targets as Google Gemini took market share. CFO Sarah Friar has...

Read more

Amazon One Medical Launches GLP-1 Weight Loss Program at $25 a Month

by Team Lumida
24 minutes ago
Amazon Targets Rural America: A Game-Changer for Delivery Services

Amazon One Medical is rolling out a weight management program that includes GLP-1 medications, offering compounded pills starting at $25/month with same-day delivery in 3,000 cities.

Read more

Florida Opens Criminal Investigation Into OpenAI Over ChatGPT’s Role in FSU Mass Shooting

by Team Lumida
6 days ago
Sam Altman’s Personal Bets Are Blurring the Line Between OpenAI’s Interests and His Own

Florida AG James Uthmeier announced a criminal probe into OpenAI after ChatGPT allegedly advised the Florida State University shooter on weapon type, ammunition, and timing — one of...

Read more

Anthropic’s Most Dangerous AI Model Has Already Been Accessed by Unauthorized Users

by Team Lumida
6 days ago
Pentagon–Anthropic Feud Escalates as AI Policy Clash Threatens Defense Contracts

A small group gained unauthorized access to Anthropic's Mythos model — capable of exploiting vulnerabilities in every major OS and browser — by combining a contractor's credentials with...

Read more

OpenAI Launches ChatGPT Images 2.0 — Now With Accurate Charts, Scientific Diagrams, and Extended Thinking

by Team Lumida
6 days ago
OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

OpenAI is rolling out ChatGPT Images 2.0 with major upgrades for professionals: better instruction-following, complex chart and scientific diagram generation, multilingual text rendering, and a new extended-compute mode...

Read more

Amazon Doubles Down on Anthropic With $5B More — and a $100B Cloud Deal That Could Reach $25B Total

by Team Lumida
7 days ago
Amazon’s $100 Billion Bet: AI Over Retail

Amazon is investing an additional $5 billion in Anthropic — with potential for up to $25 billion tied to commercial milestones — as Anthropic commits to over $100...

Read more

Chinese Robot Just Beat the Human Half-Marathon World Record — After Getting Up From a Crash

by Team Lumida
7 days ago
Chinese Robot Just Beat the Human Half-Marathon World Record — After Getting Up From a Crash

Honor's humanoid robot Lightning won Beijing's half-marathon in 50 minutes and 26 seconds — faster than any human ever — despite slamming into a barricade 220 yards from...

Read more

Marc Benioff Says the Bears Are Dead Wrong About Salesforce — AI Agents Are Just Getting Started

by Team Lumida
1 week ago
Marc Benioff Says the Bears Are Dead Wrong About Salesforce — AI Agents Are Just Getting Started

Salesforce CEO Marc Benioff pushed back hard against Wall Street skeptics, arguing that AI agent adoption is accelerating faster than critics realize and that the so-called 'SaaSpocalypse' is...

Read more

Google’s AI Chips Are the Hottest Commodity in Tech — And It’s About to Get More Serious

by Team Lumida
1 week ago
Google’s Bold AI Bet: Transforming Healthcare After Costly Missteps

Google is preparing to launch inference-specialized TPU chips at Google Cloud Next, challenging Nvidia in the fastest-growing semiconductor category as Anthropic, Meta, and Citadel pile into its custom...

Read more
Next Post
a red cube with white text

TikTok Ban Could Dent Oracle's Earnings: What Investors Need to Know

a person holding a phone

AI and Crypto Shakeup: Nvidia and Bitcoin's Massive Drops Explained

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

UnitedHealth Faces Critical Earnings Report Amid Leadership Crisis and Regulatory Pressure

UnitedHealth Group Q4 2024 Earnings Analysis

January 17, 2025
China Stimulus: Enough to Sway Markets?

Alphabet Nears $3 Trillion After Antitrust Ruling Removes Key Overhang

September 5, 2025
close-up photo of monitor displaying graph

SEC Flags Concerns Over State Street and Apollo’s Private Credit ETF Launch

February 28, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018